加科思(01167.HK) 表示，自主研发的SHP2抑制剂Sitneprotafib(JAB-3312)相关研究，已于学术期刊《临床肿瘤研究》发布，研究表明该产品显著增强了KRAS G12C抑制剂戈来雷塞在未接受治疗和耐药模型中
的抗肿瘤活性，与MEK抑制剂联合用药可显著延缓RTK信号的再启动，并增强KRAS突变癌症模型中的肿瘤生长抑制。
公司表示，Sitneprotafib与奥希替尼联合用药在奥希替尼耐药的非小细胞肺癌(NSCLC)模型中表现出优异的疗效，并通过促进抗肿瘤微环境增强了PD-1抗体的疗效。目前，加科思正在开展Sitneprotafib与戈来雷塞联用的三期临床试验，令该产品成为全球首个进入三期临床试验的SHP2抑制剂。(gc/w)(港股报价延迟最少十五分钟。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.